patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_616299 | REC_0003501 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 14.4 | 57 | female | 1 | 19 | 4.9 | 1 | alectinib 600 mg BID | 20.4 | false | MSS | 2026-03-15T05:35:57.710181+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_103937 | REC_0003502 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 12.6 | 61 | female | 1 | 13 | 6.1 | 4 | entrectinib 600 mg daily | 15 | false | MSS | 2026-03-15T05:35:57.710415+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_924714 | REC_0003503 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 13.1 | 74 | male | 0 | 16 | 4.9 | 7 | sotorasib 960 mg daily | 4 | false | MSS | 2026-03-15T05:35:57.710651+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_792556 | REC_0003504 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 14.6 | 72 | female | 3 | 15 | 6.5 | 1 | entrectinib 600 mg daily | 9.9 | true | MSI-H | 2026-03-15T05:35:57.710880+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_156337 | REC_0003505 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 13 | 13.6 | 77 | female | 2 | 11 | 4.8 | 1 | osimertinib 80 mg daily | 10.2 | true | MSI-H | 2026-03-15T05:35:57.711113+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_873084 | REC_0003506 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 30 | 6.9 | 60 | female | 1 | 87 | 5.2 | 7 | pembrolizumab 200 mg q3w | 13.5 | true | MSS | 2026-03-15T05:35:57.711343+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_160408 | REC_0003507 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 7.5 | 77 | female | 2 | 11 | 5.4 | 5 | osimertinib 80 mg daily | 8.2 | true | MSS | 2026-03-15T05:35:57.711571+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_744345 | REC_0003508 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 19 | 6.2 | 58 | female | 1 | 59 | 3.1 | 4 | pembrolizumab 200 mg q3w | 9.7 | false | MSS | 2026-03-15T05:35:57.711800+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_246392 | REC_0003509 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 13.8 | 64 | male | 0 | 9 | 7.4 | 7 | alectinib 600 mg BID | 10.5 | false | MSI-H | 2026-03-15T05:35:57.712035+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_740208 | REC_0003510 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 11.4 | 61 | male | 1 | 12 | 5.6 | 6 | alectinib 600 mg BID | 14.7 | false | MSS | 2026-03-15T05:35:57.712326+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_669610 | REC_0003511 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 10.3 | 73 | female | 1 | 19 | 6.8 | 7 | alectinib 600 mg BID | 13.3 | false | MSS | 2026-03-15T05:35:57.712629+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_538471 | REC_0003512 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 7.8 | 56 | male | 0 | 45 | 6.7 | 8 | carboplatin + paclitaxel + pembrolizumab | 11.8 | false | MSS | 2026-03-15T05:35:57.712876+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_596710 | REC_0003513 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 16 | 6.4 | 66 | female | 1 | 59 | 5.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 28.9 | false | MSS | 2026-03-15T05:35:57.713115+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_861983 | REC_0003514 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 9.7 | 63 | male | 1 | 12 | 4.9 | 1 | osimertinib 80 mg daily | 21.2 | false | MSS | 2026-03-15T05:35:57.713353+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_290915 | REC_0003515 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 14.9 | 69 | female | 0 | 13 | 6 | 7 | osimertinib 80 mg daily | 9.7 | true | MSI-H | 2026-03-15T05:35:57.713592+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_316994 | REC_0003516 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 8.5 | 90 | female | 1 | 23 | 6.8 | 4 | osimertinib 80 mg daily | 13.7 | false | MSS | 2026-03-15T05:35:57.713818+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_850256 | REC_0003517 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 3.1 | 76 | female | 1 | 19 | 5.9 | 5 | sotorasib 960 mg daily | 15.2 | false | MSS | 2026-03-15T05:35:57.714054+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_847914 | REC_0003518 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 9.4 | 61 | female | 0 | 1 | 4.4 | 6 | entrectinib 600 mg daily | 9.1 | true | MSS | 2026-03-15T05:35:57.714293+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_891459 | REC_0003519 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 20 | 8.1 | 54 | female | 0 | 12 | 3.9 | 0 | osimertinib 80 mg daily | 19.8 | false | MSS | 2026-03-15T05:35:57.714530+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_809724 | REC_0003520 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 14.6 | 70 | female | 2 | 6 | 7.2 | 7 | entrectinib 600 mg daily | 14.3 | false | MSS | 2026-03-15T05:35:57.714765+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_840054 | REC_0003521 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 7.5 | 59 | male | 0 | 16 | 4.5 | 1 | osimertinib 80 mg daily | 9.4 | false | MSS | 2026-03-15T05:35:57.714997+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_887664 | REC_0003522 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 15 | 2.5 | 68 | female | 0 | 35 | 6 | 6 | pembrolizumab 200 mg q3w | 7 | true | MSS | 2026-03-15T05:35:57.715230+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_765934 | REC_0003523 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 15.7 | 75 | female | 1 | 13 | 6.1 | 4 | osimertinib 80 mg daily | 11.7 | true | MSI-H | 2026-03-15T05:35:57.715468+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_865895 | REC_0003524 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 17.2 | 58 | male | 1 | 11 | 5 | 4 | osimertinib 80 mg daily | 12.8 | false | MSS | 2026-03-15T05:35:57.715764+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_346435 | REC_0003525 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 9.8 | 64 | female | 1 | 15 | 4.7 | 2 | sotorasib 960 mg daily | 28.1 | false | MSS | 2026-03-15T05:35:57.716001+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_788633 | REC_0003526 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 8.1 | 63 | male | 1 | 15 | 3 | 6 | sotorasib 960 mg daily | 16.2 | true | MSS | 2026-03-15T05:35:57.716337+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_890634 | REC_0003527 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 13 | 4.9 | 71 | female | 2 | 46 | 5.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 7.2 | true | MSS | 2026-03-15T05:35:57.716576+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_154941 | REC_0003528 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 9.1 | 63 | female | 0 | 13 | 6.6 | 8 | entrectinib 600 mg daily | 8.6 | true | MSS | 2026-03-15T05:35:57.716813+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_275195 | REC_0003529 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 8 | 73 | male | 2 | 22 | 3.9 | 6 | osimertinib 80 mg daily | 13.2 | false | MSS | 2026-03-15T05:35:57.717050+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_707653 | REC_0003530 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 7.5 | 66 | female | 0 | 22 | 5.5 | 1 | sotorasib 960 mg daily | 15.7 | false | MSS | 2026-03-15T05:35:57.717278+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_791279 | REC_0003531 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 7 | 77 | female | 0 | 27 | 3.1 | 6 | pembrolizumab 200 mg q3w | 11.5 | false | MSS | 2026-03-15T05:35:57.717509+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_943797 | REC_0003532 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 12 | 67 | female | 0 | 25 | 8.2 | 7 | sotorasib 960 mg daily | 4.7 | false | MSS | 2026-03-15T05:35:57.717741+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_189429 | REC_0003533 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 16 | 14.9 | 45 | female | 0 | 21 | 3.9 | 5 | osimertinib 80 mg daily | 6.7 | false | MSS | 2026-03-15T05:35:57.717975+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_218892 | REC_0003534 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 16 | 4.1 | 65 | male | 1 | 65 | 5.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 16.4 | true | MSS | 2026-03-15T05:35:57.718204+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_892634 | REC_0003535 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 34 | 10.9 | 70 | female | 1 | 8 | 2.7 | 6 | osimertinib 80 mg daily | 12.6 | false | MSS | 2026-03-15T05:35:57.718437+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_311649 | REC_0003536 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5 | 77 | female | 2 | 61 | 6.4 | 6 | carboplatin + paclitaxel + pembrolizumab | 6.2 | true | MSS | 2026-03-15T05:35:57.718666+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_348423 | REC_0003537 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 13.7 | 60 | female | 0 | 7 | 5.3 | 5 | entrectinib 600 mg daily | 5.8 | false | MSS | 2026-03-15T05:35:57.718965+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_698250 | REC_0003538 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 7.7 | 67 | male | 0 | 11 | 4.3 | 6 | osimertinib 80 mg daily | 15.3 | false | MSS | 2026-03-15T05:35:57.719206+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_559731 | REC_0003539 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 31 | 14.5 | 71 | male | 1 | 18 | 7.4 | 1 | osimertinib 80 mg daily | 24.8 | true | MSI-H | 2026-03-15T05:35:57.719455+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_596234 | REC_0003540 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 9.1 | 81 | female | 2 | 49 | 8.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.9 | false | MSS | 2026-03-15T05:35:57.719693+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_572463 | REC_0003541 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 13 | 14.4 | 72 | female | 0 | 11 | 4.1 | 2 | osimertinib 80 mg daily | 15.8 | false | MSI-H | 2026-03-15T05:35:57.719939+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_115977 | REC_0003542 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 7 | 66 | female | 1 | 48 | 5.7 | 9 | carboplatin + paclitaxel + pembrolizumab | 16.7 | true | MSS | 2026-03-15T05:35:57.720274+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_762029 | REC_0003543 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 10.2 | 68 | female | 0 | 12 | 4.7 | 6 | osimertinib 80 mg daily | 6.9 | false | MSS | 2026-03-15T05:35:57.720535+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_712837 | REC_0003544 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 13.5 | 68 | female | 0 | 26 | 6 | 2 | osimertinib 80 mg daily | 14.1 | true | MSI-H | 2026-03-15T05:35:57.720801+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_283889 | REC_0003545 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 8.2 | 71 | female | 2 | 13 | 3.9 | 7 | pembrolizumab 200 mg q3w | 9.8 | false | MSS | 2026-03-15T05:35:57.721061+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_147627 | REC_0003546 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 9.1 | 53 | female | 0 | 26 | 6.2 | 9 | sotorasib 960 mg daily | 6 | true | MSS | 2026-03-15T05:35:57.721307+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_982593 | REC_0003547 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 15.9 | 66 | female | 0 | 25 | 7.8 | 8 | entrectinib 600 mg daily | 13.9 | false | MSI-H | 2026-03-15T05:35:57.721543+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_620404 | REC_0003548 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 3.1 | 56 | female | 1 | 15 | 5.1 | 6 | pembrolizumab 200 mg q3w | 15 | true | MSS | 2026-03-15T05:35:57.721779+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_849582 | REC_0003549 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 19 | 6.9 | 76 | female | 2 | 12 | 2.2 | 1 | pembrolizumab 200 mg q3w | 14.2 | false | MSS | 2026-03-15T05:35:57.722013+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_804551 | REC_0003550 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 13.5 | 62 | male | 1 | 15 | 5.2 | 4 | osimertinib 80 mg daily | 9.5 | true | MSI-H | 2026-03-15T05:35:57.722349+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_134605 | REC_0003551 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 16.5 | 61 | male | 0 | 15 | 5.8 | 6 | osimertinib 80 mg daily | 9 | false | MSI-H | 2026-03-15T05:35:57.722595+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_628864 | REC_0003552 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 26 | 11.9 | 83 | female | 3 | 8 | 5.4 | 0 | osimertinib 80 mg daily | 39.5 | true | MSS | 2026-03-15T05:35:57.722830+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_706866 | REC_0003553 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 28 | 9.4 | 74 | female | 2 | 10 | 6.1 | 0 | osimertinib 80 mg daily | 34.8 | false | MSS | 2026-03-15T05:35:57.723060+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_888405 | REC_0003554 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 10.9 | 75 | female | 2 | 13 | 5 | 5 | osimertinib 80 mg daily | 12 | true | MSI-H | 2026-03-15T05:35:57.723290+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_282571 | REC_0003555 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 9.2 | 70 | male | 1 | 11 | 6.6 | 5 | sotorasib 960 mg daily | 11.7 | false | MSS | 2026-03-15T05:35:57.723521+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_968173 | REC_0003556 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 8.5 | 59 | female | 0 | 15 | 6.3 | 8 | entrectinib 600 mg daily | 13.3 | false | MSS | 2026-03-15T05:35:57.723751+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_175213 | REC_0003557 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 18 | 13.5 | 67 | male | 0 | 24 | 4.8 | 0 | entrectinib 600 mg daily | 41.9 | false | MSI-H | 2026-03-15T05:35:57.723986+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_602698 | REC_0003558 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 11 | 6.8 | 70 | female | 2 | 40 | 7.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 13.8 | true | MSS | 2026-03-15T05:35:57.724275+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_792202 | REC_0003559 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 10.8 | 69 | male | 1 | 15 | 4.3 | 4 | entrectinib 600 mg daily | 7.5 | false | MSI-H | 2026-03-15T05:35:57.724533+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_780210 | REC_0003560 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 3.7 | 69 | female | 1 | 17 | 6.1 | 3 | carboplatin + paclitaxel + pembrolizumab | 22.1 | true | MSS | 2026-03-15T05:35:57.724767+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_741249 | REC_0003561 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 11.7 | 66 | female | 0 | 27 | 5.1 | 5 | sotorasib 960 mg daily | 14.9 | true | MSS | 2026-03-15T05:35:57.725002+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_397762 | REC_0003562 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 15.2 | 70 | female | 2 | 27 | 6.8 | 5 | sotorasib 960 mg daily | 13.8 | false | MSI-H | 2026-03-15T05:35:57.725235+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_417448 | REC_0003563 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 12.6 | 50 | male | 0 | 16 | 6.1 | 6 | osimertinib 80 mg daily | 17.2 | false | MSS | 2026-03-15T05:35:57.725548+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_585214 | REC_0003564 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 9.6 | 55 | male | 1 | 24 | 6.6 | 7 | sotorasib 960 mg daily | 7.2 | false | MSS | 2026-03-15T05:35:57.725790+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_541027 | REC_0003565 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 21 | 10.2 | 73 | female | 2 | 21 | 6 | 0 | alectinib 600 mg BID | 42.5 | true | MSS | 2026-03-15T05:35:57.726033+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_204835 | REC_0003566 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 3.5 | 66 | female | 0 | 20 | 6.3 | 5 | alectinib 600 mg BID | 11 | false | MSS | 2026-03-15T05:35:57.726262+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_359399 | REC_0003567 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 3 | 74 | male | 3 | 12 | 2.7 | 1 | sotorasib 960 mg daily | 18.2 | true | MSS | 2026-03-15T05:35:57.726495+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_116079 | REC_0003568 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 14.3 | 67 | female | 0 | 23 | 3.8 | 1 | entrectinib 600 mg daily | 17.4 | false | MSS | 2026-03-15T05:35:57.726725+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_691889 | REC_0003569 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 5.5 | 74 | female | 2 | 25 | 7 | 6 | pembrolizumab 200 mg q3w | 9.7 | false | MSS | 2026-03-15T05:35:57.726960+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_516017 | REC_0003570 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 30 | 5.4 | 69 | female | 1 | 10 | 5 | 1 | alectinib 600 mg BID | 18.5 | false | MSS | 2026-03-15T05:35:57.727192+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_248673 | REC_0003571 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 30 | 12.5 | 59 | male | 1 | 16 | 5.1 | 6 | pembrolizumab 200 mg q3w | 9.6 | false | MSS | 2026-03-15T05:35:57.727427+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_366240 | REC_0003572 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 15.1 | 69 | female | 1 | 19 | 3.8 | 1 | osimertinib 80 mg daily | 9.4 | true | MSI-H | 2026-03-15T05:35:57.727664+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_838138 | REC_0003573 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 32 | 9.4 | 48 | female | 0 | 17 | 4.5 | 6 | sotorasib 960 mg daily | 6.5 | true | MSS | 2026-03-15T05:35:57.727894+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_239509 | REC_0003574 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 4.5 | 78 | female | 1 | 40 | 2.9 | 8 | carboplatin + paclitaxel + pembrolizumab | 8 | true | MSS | 2026-03-15T05:35:57.728173+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_871571 | REC_0003575 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 13.6 | 62 | male | 1 | 8 | 3.7 | 6 | osimertinib 80 mg daily | 18.1 | false | MSS | 2026-03-15T05:35:57.728417+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_670810 | REC_0003576 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 18 | 14.4 | 67 | male | 1 | 8 | 6.5 | 1 | alectinib 600 mg BID | 22.1 | false | MSI-H | 2026-03-15T05:35:57.728720+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_272592 | REC_0003577 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 32 | 13.6 | 70 | female | 1 | 14 | 7.4 | 2 | osimertinib 80 mg daily | 10.8 | true | MSI-H | 2026-03-15T05:35:57.728959+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_979824 | REC_0003578 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 27 | 15.8 | 53 | male | 0 | 8 | 3.6 | 0 | osimertinib 80 mg daily | 22.8 | false | MSI-H | 2026-03-15T05:35:57.729198+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_887883 | REC_0003579 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 13.2 | 69 | female | 0 | 23 | 4.9 | 5 | alectinib 600 mg BID | 15.2 | true | MSS | 2026-03-15T05:35:57.729436+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_857591 | REC_0003580 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 32 | 3.9 | 69 | female | 0 | 20 | 2.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.7 | true | MSS | 2026-03-15T05:35:57.729665+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_540098 | REC_0003581 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 7.5 | 70 | male | 1 | 13 | 6 | 1 | carboplatin + paclitaxel + pembrolizumab | 6.6 | true | MSS | 2026-03-15T05:35:57.729902+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_249796 | REC_0003582 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 10.1 | 75 | female | 1 | 10 | 4.9 | 3 | alectinib 600 mg BID | 21.5 | true | MSI-H | 2026-03-15T05:35:57.730140+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_616001 | REC_0003583 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 17.5 | 68 | female | 1 | 15 | 3.2 | 7 | osimertinib 80 mg daily | 12.3 | false | MSS | 2026-03-15T05:35:57.730383+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_245274 | REC_0003584 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 10.3 | 70 | female | 1 | 13 | 5.7 | 9 | sotorasib 960 mg daily | 6.5 | false | MSI-H | 2026-03-15T05:35:57.730666+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_364465 | REC_0003585 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 12.1 | 52 | male | 0 | 9 | 3.8 | 2 | osimertinib 80 mg daily | 6.9 | false | MSS | 2026-03-15T05:35:57.730940+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_895821 | REC_0003586 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 12.4 | 65 | female | 0 | 12 | 5.2 | 7 | sotorasib 960 mg daily | 13.7 | false | MSS | 2026-03-15T05:35:57.731183+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_689554 | REC_0003587 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 10.9 | 70 | female | 3 | 13 | 5.3 | 2 | osimertinib 80 mg daily | 12.1 | true | MSI-H | 2026-03-15T05:35:57.731423+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_268608 | REC_0003588 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 11.3 | 49 | male | 0 | 14 | 5.6 | 8 | entrectinib 600 mg daily | 8.4 | false | MSI-H | 2026-03-15T05:35:57.731659+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_965695 | REC_0003589 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 18 | 17.5 | 75 | female | 2 | 12 | 4.6 | 1 | sotorasib 960 mg daily | 27.9 | false | MSI-H | 2026-03-15T05:35:57.732018+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_854708 | REC_0003590 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 7 | 79 | male | 1 | 39 | 8.1 | 7 | carboplatin + paclitaxel + pembrolizumab | 8.7 | false | MSS | 2026-03-15T05:35:57.732331+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_832025 | REC_0003591 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 16.1 | 79 | female | 1 | 16 | 6.5 | 2 | osimertinib 80 mg daily | 27.2 | true | MSI-H | 2026-03-15T05:35:57.732569+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_525727 | REC_0003592 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 14.5 | 66 | female | 0 | 12 | 6.2 | 4 | entrectinib 600 mg daily | 7.2 | true | MSS | 2026-03-15T05:35:57.732804+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_466392 | REC_0003593 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 11 | 9.8 | 76 | female | 0 | 71 | 4.1 | 9 | carboplatin + paclitaxel + pembrolizumab | 11 | true | MSS | 2026-03-15T05:35:57.733043+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_362514 | REC_0003594 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 6.7 | 67 | female | 1 | 12 | 8.4 | 5 | sotorasib 960 mg daily | 10.7 | false | MSS | 2026-03-15T05:35:57.733272+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_900320 | REC_0003595 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 9.6 | 68 | female | 1 | 10 | 4 | 0 | entrectinib 600 mg daily | 25 | true | MSS | 2026-03-15T05:35:57.733499+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_219793 | REC_0003596 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 11.6 | 62 | female | 1 | 15 | 4.4 | 5 | osimertinib 80 mg daily | 7.3 | true | MSI-H | 2026-03-15T05:35:57.733732+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_676550 | REC_0003597 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 8.7 | 56 | male | 0 | 7 | 6.8 | 3 | sotorasib 960 mg daily | 15.4 | true | MSS | 2026-03-15T05:35:57.733967+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_703420 | REC_0003598 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 13.1 | 61 | female | 0 | 26 | 8 | 5 | osimertinib 80 mg daily | 17.9 | true | MSI-H | 2026-03-15T05:35:57.734202+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_101098 | REC_0003599 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 32 | 9.2 | 57 | female | 0 | 21 | 6 | 1 | sotorasib 960 mg daily | 16.1 | false | MSS | 2026-03-15T05:35:57.734437+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_158294 | REC_0003600 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 7 | 71 | male | 1 | 11 | 4.2 | 3 | osimertinib 80 mg daily | 20 | true | MSS | 2026-03-15T05:35:57.734669+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.